Dyne Therapeutics Inc (DYN) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Dyne Therapeutics Announces Key Leadership Appointments

- Building Team to Prepare for Commercialization as Company Pursues Expedited Approval Pathways for DM1 and DMD...

Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts

- Initiating Registrational Cohorts with Update on Path to Registration by Year-End 2024 -- Virtual Investor...

Form 4 - Statement of changes in beneficial ownership of securities

Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage...